Tissue Regenix Group PLC New appointment adds clinical expertise to Board (7824Z)
June 01 2016 - 2:01AM
UK Regulatory
TIDMTRX
RNS Number : 7824Z
Tissue Regenix Group PLC
01 June 2016
Tissue Regenix Group plc
New appointment adds clinical expertise to Board
Leeds, 1 June, 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
today announces that it has appointed Professor Shervanthi Homer -
Vanniasinkam as a Non- Executive Director with immediate
effect.
Professor Homer-Vanniasinkam is a respected Consultant Vascular
Surgeon who holds a number of appointments at medical and academic
institutions across the country, and is regularly invited to
lecture at prestigious establishments across the world. She was
recently appointed to the First Chair of Engineering and Surgery at
University College London, and currently holds positions which
include Clinical Sub - Dean, University of Leeds Medical School and
Professor of Surgery University of Warwick Medical School and
University Hospitals Coventry and Warwickshire. Professor
Homer-Vanniasinkam has been acting as a clinical advisor to the
Group for a number of years and has extensive experience of medical
research, development and innovation.
John Samuel, Chairman of Tissue Regenix Group commented: "We
welcome the appointment of Shervanthi as a Non- Executive Director,
having supported Tissue Regenix in an advisory role for a number of
years. With a strong commercially - focussed Board we feel it
imperative to match this with clinical expertise as the Group
continues to grow and bring dCELL(R) to the market. The appointment
of Shervanthi at this time highlights the continued momentum of
Tissue Regenix as we expand further into the US marketplace and
bring human tissue applications to Europe."
Further Information:
Full Name: Shervanthi Homer- Vanniasinkam
Age: 58
Other Corporate Board positions: N/A
Present Appointments:
Consultant Vascular Surgeon, Leeds Vascular Institute, Leeds
General Infirmary
Clinical Sub-Dean, University of Leeds Medical School &
Director of EXSEL@Leeds
Professor of Surgery (Founding), University of Warwick Medical
School &
University Hospitals Coventry and Warwickshire
Professor of Engineering and Surgery, University College
London
There is no further information to be disclosed in accordance
with the requirements of Schedule Two paragraph (g) of the AIM
rules.
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Officer
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAWGUMAAUPQGCG
(END) Dow Jones Newswires
June 01, 2016 02:01 ET (06:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Oct 2023 to Oct 2024